Results 1 to 10 of about 8,722 (208)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy [PDF]

Molecules, 2020
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads
Nicolas Lepareur, Mickael Bourgeois, Pascal Loyer   +2 more
exaly   +4 more sources

²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic [PDF]

Pharmaceutics, 2023
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira, Emmanuel Deshayes, Lore Santoro, Pierre Olivier Kotzki, Cyril Fersing   +4 more
doaj   +2 more sources

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors [PDF]

BMC Cancer, 2019
Background Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs.
Florian Bösch, Alexandr V. Bazhin, Sabine Heublein, Katharina Brüwer, Thomas Knösel, Florian P. Reiter, Christoph J. Auernhammer, Markus O. Guba, Christine Spitzweg, Jens Werner, Martin K. Angele   +10 more
doaj   +2 more sources

A case of malignant insulinoma responsive to somatostatin analogs treatment [PDF]

BMC Endocrine Disorders, 2018
Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and ...
Mariasmeralda Caliri, Valentina Verdiani, Edoardo Mannucci, Vittorio Briganti, Luca Landoni, Alessandro Esposito, Giulia Burato, Carlo Maria Rotella, Massimo Mannelli, Alessandro Peri   +9 more
doaj   +2 more sources

A review of the use of somatostatin analogs in oncology

OncoTargets and Therapy, 2013
Somatostatin is a neuropeptide produced by paracrine cells that are located throughout the gastrointestinal tract, lung, and pancreas, and is also found in various locations of the nervous system. It exerts neural control over many physiological functions including inhibition of gastrointestinal endocrine secretion through its receptors.
Suayib Yalcin, Özge Keskin
exaly   +6 more sources

Somatostatin analogs in endothelial dysfunction. [PDF]

Am J Physiol Endocrinol Metab
Barabutis N.
europepmc   +3 more sources

The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis [PDF]

Journal of Clinical Medicine, 2022
Riccardo Casadei, Claudio Ricci, Davide Campana   +2 more
exaly   +2 more sources

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

Frontiers in Endocrinology, 2021
Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease.
Mayank Patel, Isabel Tena, Isabel Tena, Abhishek Jha, David Taieb, Karel Pacak   +5 more
doaj   +1 more source

Somatostatin Analogs in Clinical Practice: A Review [PDF]

International Journal of Molecular Sciences, 2020
Jersy Jair Cárdenas, Cristina Alvarez-Escolá   +1 more
exaly   +2 more sources

Somatostatin analogs: is one better than other? [PDF]

Therapeutic Advances in Medical Oncology, 2017
Rossana Berardi, Stefano Partelli, Stefano Cascinu, Massimo Falconi   +3 more
doaj   +2 more sources